

Please type a plus sign (+) inside this box → ☐

03-16-01

PTO/SB/05 (08-00)

Approved through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. PH-7134

First Inventor or Application Identifier Copeland et al

Title PEPTIDASE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR THERAPEUTIC USE

Express Mail Label No. EL387242709US

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.
See 37 CFR 1.27.
3. ☒ Specification [Total Pages 104]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s) = 39
 - Abstract of the Disclosure
4. ☐ Drawing(s) (35 U.S.C.113) [Total Sheets 2]
5. Oath or Declaration [Total Pages 2]
 - a. ☐ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 CFR 1.63 (d))
(for a continuation/divisional with Box 17 completed)
 - i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☒ Application Data Sheet. See 37 CFR 1.76

ADDRESS TO

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☒ Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☒ paper
 - c. ☒ Statements verifying identity of above copies

ACCOMPANYING APPLICATIONS PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 C.F.R. §3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Other:

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)

of prior application No: ____ /

Prior application information: Examiner ____

Group Art Unit:

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

☒ Customer Number 24348



24348

PATENT TRADEMARK OFFICE

or ☐ Correspondence address below

Name	SCOTT K. LARSEN				
Address	DuPont Pharmaceuticals Company - c/o E.I. duPont de Nemours and Co. 1007 Market Street				
City	Wilmington	State	Delaware	Zip Code	19898
Country	U.S.A.	Telephone	(302) 992-2368	Fax	(302) 892-8536

Name (Print/Type)	Scott K. Larsen	Registration No. (Attorney/Agent)	38,532
Signature		Date	March 15, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**FEE TRANSMITTAL
for FY 2001**

Patent fees are subject to annual revision.

Complete if Known

Application Number	Unknown
Filing Date	March 15, 2001
First Named Inventor	Copeland et al
Examiner Name	Unknown
Group / Art Unit	Unknown
Attorney Docket No.	PH-7134

TOTAL AMOUNT OF PAYMENT (\$) 1052.00

METHOD OF PAYMENT (check one)		FEE CALCULATION (continued)	
1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:		3. ADDITIONAL FEES	
Deposit Account Number	04-1928		
Deposit Account Name	DuPont Pharmaceuticals Company		
<input checked="" type="checkbox"/> Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17			
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27			
2. <input type="checkbox"/> Payment Enclosed:			
<input type="checkbox"/> Check <input type="checkbox"/> Credit card <input type="checkbox"/> Money Order <input type="checkbox"/> Other			
FEE CALCULATION			
1. BASIC FILING FEE			
Large Entity Fee Code	Small Entity Fee Code	Fee (\$)	Fee Description
105	205	130	Surcharge - late filing fee or oath
127	227	50	Surcharge - late provisional filing fee or cover sheet.
139	139	130	Non-English specification
147	147	2,520	For filing a request for ex parte reexamination
112	112	920*	Requesting publication of SIR prior to Examiner action
113	113	1,840*	Requesting publication of SIR after Examiner action
115	215	110	Extension for reply within first month
116	216	390	Extension for reply within second month
117	217	890	Extension for reply within third month
118	218	1,390	Extension for reply within fourth month
128	228	1,890	Extension for reply within fifth month
119	219	310	Notice of Appeal
120	220	310	Filing a brief in support of an appeal
121	221	270	Request for oral hearing
138	138	1,510	Petition to institute a public use proceeding
140	240	110	Petition to revive - unavoidable
141	241	1,240	Petition to revive - unintentional
142	242	1,240	Utility issue fee (or reissue)
143	243	440	Design issue fee
144	244	600	Plant issue fee
122	122	130	Petitions to the Commissioner
123	123	130	Petitions related to provisional applications
126	126	240	Submission of Information Disclosure Stmt
581	581	40	Recording each patent assignment per property (times number of properties)
146	246	710	Filing a submission after final rejection (37 CFR § 1.129(a))
149	249	710	For each additional invention to be examined (37 CFR § 1.129(b))
179 (RCE)	279	710	Request for Continued Examination
169	169	900	Request for expedited examination of a design application
SUBTOTAL (1)		(\$ 710.00)	
2. EXTRA CLAIM FEES			
Total Claims	39	-20**	= 19
Independent Claims	1	-3**	= 0
Multiple Dependent			= 0
Extra Claims	19	X	Fee from below
Fee from below	18	=	Fee Paid
Fee Paid	342		
Large Entity Fee Code	Small Entity Fee Code	Fee (\$)	Fee Description
103	203	18	Claims in excess of 20
102	202	80	Independent claims in excess of 3
104	204	270	Multiple dependent claim, if not paid
109	209	80	** Reissue independent claims over original patent
110	210	18	** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2)		(\$ 342.00)	
*or number previously paid, if greater; For Reissues, see above			
SUBMITTED BY		Complete (if applicable)	
Name (Print/Type)	Scott K. Larsen	Registration No. Attorney/Agent	38,532
Signature		Telephone	302-992-2368
		Date	March 15, 2001
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.			
Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.			